Late-breaking Data Show Esprit BTK Drug-eluting Resorbable S

Abbott's landmark LIFE-BTK randomized clinical trial met its primary safety and effectiveness endpoints, demonstrating that Esprit BTK offers significant advancements in opening and keeping blocked arteries below-the-knee open compared to the standard of care, balloon angioplasty 

Related Keywords

United States , San Francisco , California , Jennifer Jones Mcmeans , Juan Granada , Ian Meredith , Patrick Serruys , Stephen Ellis , Ajay Kirtane , Brian Derubertis , Current State Of Bioresorbable Stent Technology , Drug Administration , Weill Cornell Medical Center , Development Efforts In Cardiovascular Medicine , Eluting Resorbable Scaffold System , Transcatheter Cardiovascular Therapeutics , New England Journal , Resorbable Stent Content , Bioresorbable Stent Technology , Current State , Bioresorbable Stents , Poor Outcomes , Small Coronary Arteries , Gregg Stone , What Went Wrong With , Bioresorbable Stent Comparable , Two Years , With Concerns , Bioresorbable Stent Failure Modes , Patient Selection , Future Development , Future Research , Development Efforts , Cardiovascular Medicine , Professor Ian Meredith ,